海辰药业(300584) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥150,605,102.60, a decrease of 7.15% compared to ¥162,203,581.18 in the same period last year[4] - Net profit attributable to shareholders was ¥12,620,961.53, down 6.58% from ¥13,509,866.40 year-on-year[4] - Basic earnings per share decreased to ¥0.1052, down 6.57% from ¥0.1126 in the same period last year[4] - Total operating revenue for Q1 2022 was CNY 150,605,102.60, a decrease of 7.83% from CNY 162,203,581.18 in Q1 2021[23] - Net profit for Q1 2022 was CNY 12,448,499.59, a decline of 6.39% compared to CNY 13,297,482.78 in Q1 2021[24] Cash Flow - The net cash flow from operating activities was -¥40,136,476.98, a significant decline of 321.09% compared to ¥18,153,992.05 in the previous year[4] - Cash received from sales of goods and services in Q1 2022 was CNY 121,681,320.26, down from CNY 178,421,659.53 in Q1 2021[27] - The net cash flow from investment activities was 23,247,822.60 CNY, recovering from a negative cash flow of -7,659,685.62 CNY in the previous year[28] - The total cash outflow from operating activities was 174,462,859.63 CNY, compared to 160,649,033.98 CNY in the previous year, indicating higher operational costs[28] - The company paid 21,065,428.43 CNY in taxes, down from 27,214,092.77 CNY in the previous year, suggesting a potential decrease in taxable income[28] Assets and Liabilities - Total assets increased by 1.36% to ¥1,319,690,403.80 from ¥1,302,008,303.05 at the end of the previous year[7] - The company's total current assets at the end of the reporting period were 501.33 million yuan, compared to 301.96 million yuan at the beginning of the year[19] - Total liabilities as of the end of Q1 2022 were CNY 358,842,603.35, slightly up from CNY 353,530,387.82 in Q1 2021[21] - The company's total equity as of the end of Q1 2022 was CNY 960,847,800.45, an increase from CNY 948,477,915.23 in Q1 2021[21] Research and Development - The company's R&D expenses decreased by 37.61% to ¥4,789,264.33 from ¥7,676,524.25 year-on-year[9] - Research and development expenses for Q1 2022 were CNY 4,789,264.33, a decrease of 37.73% from CNY 7,676,524.25 in Q1 2021[24] Sales Performance - Sales of injectable Lantanol increased significantly, reaching 25.22 million yuan, a year-on-year increase of 34,617%[14] - The sales volume of injectable Lantanol reached 181,100 units, up 125,669% year-on-year[14] - Sales of Rivaroxaban tablets amounted to 14.86 million yuan, maintaining stable sales despite the impact of the Spring Festival and the pandemic[14] Investment Activities - The company’s cash flow from investing activities was ¥23,247,822.60, a significant improvement from -¥7,659,685.62 in the previous year[9] - Total cash inflow from investment activities was 246,432,426.11 CNY, a substantial increase from 30,062,166.66 CNY year-over-year[28] - The cash inflow from recovering investments was 246,412,538.11 CNY, a notable increase from 30,062,166.66 CNY in the previous year, highlighting improved investment recovery efforts[28] Borrowings and Equity - The company’s short-term borrowings decreased by 34.00% to ¥66,069,130.56 from ¥100,109,270.85[9] - Deferred income tax liabilities decreased to CNY 22,293,792.09 from CNY 41,466,021.50 in the previous year[21]